e-learning
resources
Barcelona 2013
Sunday, 08.09.2013
New drugs in respiratory medicine
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
DEAE-dextran MMA copolymer non-viral vector for aerosol therapy in respiratory diseases
K. Darwiche, P. Zarogoulidis, C. Ritzoulis, W. Hohenforst-schmidt, L. Sakkas, A. Cheva, A. Sakkas, D. Spyratos, D. Sparopoulou, K. Zarogoulidis (Essen, Coburg, Germany; Thessaloniki, Greece)
Source:
Annual Congress 2013 –New drugs in respiratory medicine
Session:
New drugs in respiratory medicine
Session type:
Poster Discussion
Number:
1599
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K. Darwiche, P. Zarogoulidis, C. Ritzoulis, W. Hohenforst-schmidt, L. Sakkas, A. Cheva, A. Sakkas, D. Spyratos, D. Sparopoulou, K. Zarogoulidis (Essen, Coburg, Germany; Thessaloniki, Greece). DEAE-dextran MMA copolymer non-viral vector for aerosol therapy in respiratory diseases. Eur Respir J 2013; 42: Suppl. 57, 1599
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Evidence-based eHealth for COPD
Related content which might interest you:
Development of a novel nano-sized carrier system for aeroseol drug delivery (EGE University translational pulmonology research group)
Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD
Year: 2015
Anti-IgE as an alternative treatment for occupational asthma due to low molecular weight agents
Source: International Congress 2016 – Occupational and environmental exposures and biomarkers: human studies, animal data, and in vitro methods
Year: 2016
Effect of diminazene on monocrotalin-induced pulmonary hypertension rat model
Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease
Year: 2015
Developing a chronic murine model that better reflects the clinical features of the human asthma
Source: International Congress 2016 – Pharmacological intervention in humans and murine models of asthma
Year: 2016
Intratracheal administration of dry powdered low-molecular-weight chitosan/siRNA complexes suppressed gene expression in the airway, alveoli, and metastatic tumors in murine lung
Source: Annual Congress 2013 –New drugs in respiratory medicine
Year: 2013
Characterisation of an experimental mouse model of exposure to nanoparticles. Relevance to human sarcoidosis
Source: International Congress 2015 – Sarcoidosis: clinical
Year: 2015
Animal models in drug development
Source: Research Seminar 2013 - Optimising models for human lung diseases and drug development
Year: 2013
Deposition and pulmonary effect of nanoparticle in whole body inhalation study and in nose only inhalation study
Source: International Congress 2015 – Occupational and environmental effects: in vitro and animal models
Year: 2015
Mesoporous silica-based nanoparticles for targeted delivery of proteasome inhibitors to the lung
Source: Annual Congress 2013 –Cutting edge: drug delivery to the airways
Year: 2013
Effects of tobacco smoke and poly IC, alone and in combination, on mouse lung pathology
Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases
Year: 2013
RIG-I receptors induced by dsRNA challenges in an HDM-mouse model of asthma exacerbation
Source: International Congress 2014 – Exploring molecular mechanisms of allergy and asthma in animal models
Year: 2014
Engineered gold nanoparticles targeted to mesenchymal cells from BOS patients can be safely administered to normal mice by inhalation
Source: International Congress 2015 – Pathogenic mechanisms of lung transplant complications: a focus on CLAD
Year: 2015
Simulation of particle deposition in the human airways
Source: Annual Congress 2013 –Airway calibre, airway challenge and assessment of oxygenation
Year: 2013
Biodistribution of engineered hematite nanoparticles in healthy and asthmatic mice
Source: Annual Congress 2013 –Environmental and occupational respiratory diseases: new exposure assessment methods, experimental exposure in animal and humans and mechanisms
Year: 2013
Development of a lung slice methodology to study the mechanisms of lung uptake and lysosomal trapping
Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases
Year: 2014
Mepenzolate bromide displays beneficial effects in a mouse model of chronic obstructive pulmonary disease
Source: International Congress 2014 – Animal models in respiratory drug development
Year: 2014
A new model for analysis of chronic bronchial interleukin-8 expression
Source: International Congress 2016 – Airway response to infection
Year: 2016
Respiratory consequences of fluid replacement with autologous blood or colloid solution after acute haemorrhage in rats
Source: Annual Congress 2013 –Clinical physiology and functional imaging in health and disease
Year: 2013
Pre-clinical to clinical potency of AZD7624 in LPS induced TNFa response
Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept